Redcare Pharmacy Shares Surge on Proposed Healthcare Overhaul

Redcare Pharmacy's stock rallies over 20% as a proposal to raise prescription co-payments sparks a short squeeze, highlighting its dominant Rx segment.

A dramatic shift in sentiment has caught short sellers off guard at online pharmacy group Redcare Pharmacy. Following an extended period of decline, the company's stock has staged a powerful rally, driven by a comprehensive set of proposals to reform Germany's healthcare financing. This political development has abruptly refocused investor attention on the firm's lucrative prescription medication segment as its core growth engine, even as its over-the-counter business continues to face challenges.

Operational Performance: A Mixed Picture

The timing of this political debate is strategically significant for Redcare. The prescription drug (Rx) division, which now commands a 67% market share in Germany, has solidified its position as the company's central pillar. This standing is reinforced by a key structural advantage: competitor Rossmann has confirmed that its planned online pharmacy will not offer prescription medicines.

In contrast, the over-the-counter (OTC) segment remains a persistent concern. The market entry of chains like dm and Rossmann has placed noticeable pressure on margins. Management recently revised its growth expectations for this division downward, from 16% to a range of 8-10%. The medium-term target margin for adjusted EBITDA in this area was also lowered from 8% to 5%.

Prescription Price Hike Proposal Ignites Rally

The catalyst for the sudden share price appreciation was the initial report from the FinanzKommission Gesundheit (Health Finance Commission) released in late March. The expert panel presented 66 recommendations aimed at averting a looming multi-billion euro deficit in the statutory health insurance system. One specific detail has captured market imagination: the proposal to increase prescription co-payments by 50%, from the current range of five to ten euros to between 7.50 and 15 euros.

Market expert Felix Dennl of Bankhaus Metzler identifies a clear potential benefit for the mail-order pharmacy sector. He suggests that higher out-of-pocket costs are likely to incentivize price-sensitive patients to switch from local brick-and-mortar pharmacies to more affordable online providers.

This prospect of additional business triggered a short squeeze, as many investors had previously bet on further price declines. Short sellers were forced to hastily cover their positions by buying shares, resulting in a jump of over 20% in just two trading sessions. Despite this rapid ascent, the stock remains down approximately 44% year-to-date. This performance continues to place it second-to-last in the MDAX ranking for 2026, just ahead of Auto1 Group.

Political Process and Upcoming Milestones

Whether the reform proposal becomes law will be determined by the coalition government's political process. Health Minister Nina Warken aims for a cabinet decision by the end of July, which would allow the changes to take effect at the beginning of 2027.

Irrespective of the political outcome in Berlin, investors are looking ahead to two imminent corporate events:

• 15 April 2026: Annual General Meeting, featuring the formal election of the new CFO, Hendrik Krampe.
• 06 May 2026: Publication of first-quarter financial results.

The upcoming quarterly report is anticipated to provide the first concrete evidence on whether the company's targeted revenue of 670 million euros in the Rx segment for the current year remains achievable and if it can sufficiently offset the ongoing softness in OTC operations.